Plastic Eating Fungus Discovered in Pakistan by Chinese Scientists

Published in News
Sunday, 17 September 2017 23:37
In Quick

Researchers have recognized a fungus which can damage down plastics. The species could be a beneficial device as we strive to lessen the impact of waste fabric at the surroundings.

Fungi feast

Researchers at the Chinese Academy of Sciences’ Kunming Institute of Botany have discovered a fungus that could doubtlessly assist us to deal with the trouble of non-biodegradable plastics. The fungus is ready to break down waste plastics in a depend on weeks that might in any other case persist in the environment for years.

Aspergillus tubingensis is commonly observed in soil, however, the have a look at observed that it is able to additionally thrive at the surface of plastics. It secretes enzymes which smash down the bonds between person molecules after which use its mycelia to break them aside.
 
It’s conceivable that there are all types of fungi with beneficial properties that we don’t but know approximately — but as deforestation and different human activity hold to spoil habitats, we would never advantage get admission to such species. The researchers actually found Aspergillus tubingensis on a rubbish unload in Islamabad, Pakistan.
 
Plastic Capability
 
The have a look at found that there are several elements that affect the fungus’ capability to interrupt down plastic. The temperature and pH stability of its environment, in addition to the kind of lifestyle medium in the vicinity, had an impact on its performance.
 
The following step for those researchers is to figure out what conditions might be ideal to help facilitate a realistic implementation.
 
The fungus might be used to assist address the problem of plastic particles swimming around in our water supply via being put to paintings in a waste remedy plant, or in soil contaminated with the cloth. The benefits of mycoremediation — the exercise of the usage of fungi to degrade undesirable substances — have become increasingly more apparent as we discover species which could degrade extra varieties of fabric.

Scientists develop new antibiotic for gonorrhea

Published in News
Friday, 03 March 2017 20:11

Scientists at the University of York have harnessed the therapeutic effects of carbon monoxide-releasing molecules to develop a new antibiotic which could be used to treat the sexually transmitted infection gonorrhoea.

The infection, which is caused by the bacteria Neisseria gonorrhoeae, has developed a highly drug-resistant strain in recent years with new cases reported in the north of England and Japan.

There are concerns that gonorrhoea, which is the second most common sexually transmitted infection in England, is becoming untreatable.

Almost 35,000 cases were reported in England during 2014, with most cases affecting young men and women under the age of 25. The interdisciplinary team, from the University of York's Departments of Biology and Chemistry, targeted the "engine room" of the bacteria using carbon monoxide-releasing molecules (CO-RMs).

CO is produced naturally in the body, but there is increasing evidence that carbon monoxide enhances antibiotic action with huge potential for treating bacterial infections.

The scientists found that Neisseria gonorrhoeae is more sensitive to CO-based toxicity than other model bacterial pathogens, and may serve as a viable candidate for antimicrobial therapy using CO-RMs.

The CO molecule works by binding to the bacteria, preventing them from producing energy.

Scientists believe the breakthrough, published in the journal MedChemComm, could pave the way for new treatments.

Professor Ian Fairlamb, from the University's Department of Chemistry, said: "The carbon monoxide molecule targets the engine room, stopping the bacteria from respiring. Gonorrhoea only has one enzyme that needs inhibiting and then it can't respire oxygen and it dies.

"People will be well aware that CO is a toxic molecule but that is at high concentrations. Here we are using very low concentrations which we know the bacteria are sensitive to.

"We are looking at a molecule that can be released in a safe and controlled way to where it is needed."

The team say the next stage is to develop a drug, either in the form of a pill or cream, so that the fundamental research findings can be translated on to future clinical trials.

Professor Fairlamb added: "We think our study is an important breakthrough. It isn't the final drug yet but it is pretty close to it." "People might perceive gonorrhoea as a trivial bacterial infection, but the disease is becoming more dangerous and resistant to antibiotics."

The team worked with Professor James Moir from the University's Department of Biology. He added: "Antimicrobial resistance is a massive global problem which isn't going away. We need to use many different approaches, and the development of new drugs using bioinorganic chemistry is one crucial way we can tackle this problem, to control important bacterial pathogens before the current therapies stop working."

Miss Microbiologist: Chalita Suansane (Miss Universe)

Published in News
Friday, 03 March 2017 19:49

Chalita Suansane is a 21 year old Thailand native currently studying Microbiology at Mahasarakham University. Ever since Suansane was young, she was often curious and eager to learn new things, including a passion to explore living organisms that you cannot see by the eyes. On top of her studies, Suansane volunteers at ‘Baan Home Hug’ which is an orphanage that houses children who have inherited HIV from their parents, children who were abused, and children who have lost their family. If crowned, she would like to raise awareness and advocate for HIV/AIDS. Suansane would also like to let young women know that fulfilling your own passions, having self-respect, and being compassionate to others will make you confidently beautiful in your own way.

Towards a cure for herpesviruses: Targeting infection with CRISPR/Cas9

Published in Informative
Tuesday, 22 November 2016 13:35

Most adults carry multiple herpesviruses. Following the initial acute infection, these viruses establish life-long infections in their hosts and cause cold sores, keratitis, genital herpes, shingles, infectious mononucleosis, and other diseases. Some herpesviruses can cause cancer in man. During the latent phase of infection, the viruses remain dormant for long periods of time, but retain the capacity to cause occasional reactivations, that may lead to disease. A study published on June 30th in PLOS Pathogens suggests that attacking herpesvirus DNA with CRISPR/Cas9 genome editing technology can suppress virus replication and, in some cases, lead to elimination of the virus.

The CRISPR/Cas9 system targets specific DNA sequences and induces clean cuts across both strands of the DNA. In mammalian cells, such cuts are flagged and quickly repaired by an emergency repair system called NHEJ (for non-homologous end-joining). NHEJ is efficient but not very accurate and often results in insertion or deletion of a few DNA bases at the repair site. Because DNA is read in codons of three bases at a time, such small changes in critical positions often destroy the function of the respective gene and its protein product.

Robert Jan Lebbink, from the University Medical Center in Utrecht, The Netherlands, and colleagues reasoned that CRISPR/Cas9 could target and mutate latent herpesvirus DNA in infected human cells and so potentially prevent herpesvirus-associated diseases. To test this, the researchers devised specific guide (g)RNAs—sequences that are complementary to vital parts of the viral genome and function as 'molecular addresses'. These gRNAs, combined with the 'molecular scissors' part of the CRISPR/Cas9 system, should induce specific cuts and subsequent mutations in the herpesvirus DNA, and so cripple the viruses.

In their systematic approach, the researchers looked at three different members of the herpesvirus group: herpes simplex virus type 1 (HSV-1) causing cold sores and herpes keratitis; human cytomegalovirus (HCMV), the most common viral cause of birth defects (when the virus is transmitted from mother to fetus); and Epstein-Barr virus (EBV) causing infectious mononucleosis and multiple types of cancer.

Working with lymphoma cells latently infected with EBV, the researchers showed that introduction of gRNAs that target specific EBV DNA sequences can introduce mutations at the targeted sites. Such mutations can eliminate essential functions of the virus as well as de-stabilize the viral DNA molecules. Consistent with this, the researchers report that by using two different gRNAs targeting an essential EBV gene, they can induce loss of over 95% of EBV genomes from the host cells.

During latent infection, HCMV genomes exist as circular DNA molecules in the nucleus of host cells. Upon virus reactivation, HCMV replication proceeds slowly. With appropriate gRNAs, the researchers found that CRISPR/Cas9 editing can efficiently impair HCMV replication. However, they also observed emergence of escape variants that bypass CRISPR/Cas9 editing, suggesting that simultaneous editing at multiple critical sites in the HCMV genome is necessary to avoid the development of resistant genomes.

Compared to HCMV, HSV-1 multiplies much faster. When the researchers tested various gRNAs targeting different essential HSV-1 genes in conjunction with CRISPR/Cas9, they found that many of them were able to reduce virus replication. When they combined two of those gRNAs, thereby simultaneously targeting two essential genes, they were able to completely suppress HSV-1 replication. On the other hand, they were unable to induce editing during the latent phase, i.e. when the viral DNA was not actively multiplying.

"We observed highly efficient and specific clearance of EBV from latently infected tumor cells and impairment of HSV-1 and HCMV replication in human cells", the researchers summarize. They go on to say, "although CRISPR/Cas9 was inefficient at directing genome engineering of quiescent HSV-1, virus replication upon reactivation of quiescent HSV-1 was efficiently abrogated using anti-HSV-1 gRNAs". Their results, they hope, "may allow the design of effective therapeutic strategies to target human herpesviruses during both latent and productive infections."

New evolutionary finding: Species take different genetic paths to reach same trait

Published in News
Thursday, 27 October 2016 00:49
Biologists have been contemplating evolutionary change since Charles Darwin first explained it.
 
Using modern molecular tools and fieldwork, University of Nebraska-Lincoln biologist Jay Storz and colleagues have demonstrated for the first time that different species can take different genetic paths to develop the same trait. The team's findings appear in the Oct. 21 issue of the journal Science.
 
"There's this really long-standing question in evolutionary genetics about the predictability of genetic change," said Storz, Susan J. Rosowski professor of biological sciences.
 
In other words, did species with a common, beneficial trait undergo the same genetic changes to evolve that trait? Or did the trait develop through different, and therefore unpredictable, genetic paths?
 
It turns out that natural selection, a primary evolutionary process, can dependably produce similar, beneficial traits in different species. But at the molecular level, the evolutionary changes tend to be highly idiosyncratic, and are therefore far less predictable.
 
To find that out, Storz turned to birds living in South America's Andes Mountains. Comparing high-altitude bird species with their lowland counterparts, his team determined that the high-altitude birds had evolved red blood cells with hemoglobin proteins that more readily bind oxygen molecules. This trait benefits species living in low-oxygen settings, such as the mountains.
 
Storz and his team tested the hemoglobin proteins from numerous high-altitude bird species and identified which differences, or mutations, in the proteins' makeup were responsible for the high-altitude trait. In most cases, the change in protein function among the different species was caused by different mutations.
 
"What this indicates is that there are many possible mutations that can all produce the same phenotypic effect (trait)," Storz said. "We can't predict which particular mutations are responsible for these changes." One possible reason for this variability is that during evolution, the hemoglobins of different species have each accumulated their own unique set of mutations. Given these distinct genetic backgrounds, a mutation that produces a beneficial effect in one species may produce a detrimental effect in a different species.
 
To test this theory, Storz's team used genetic engineering tools to reconstruct and resurrect the hemoglobin proteins of several ancestral bird species, including the ancestor common to all birds, which existed more than 100 million years ago. Engineering the high-altitude hemoglobin mutations into the ancient bird proteins resulted in vastly different effects than in contemporary birds.
 
As evolution advances through time, different mutations accumulate in distinct species and settings. Natural selection applies similar pressures for species to adapt as they move to higher altitudes, for example, but the adaptation must take different genetic paths to get there.
 
"This is a new phenomenon that our findings have helped reveal," Storz said. His team continues to explore historical influences on genetic adaptation.
 

Source: Materials provided by University of Nebraska-Lincoln. Note: Content may be edited for style and length.

Zika Virus Infection Alters Human and Viral RNA

Published in News
Monday, 24 October 2016 22:14
Researchers at University of California San Diego School of Medicine have discovered that Zika virus infection leads to modifications of both viral and human genetic material. These modifications — chemical tags known as methyl groups — influence viral replication and the human immune response. The study is published October 20 by Cell Host & Microbe.
 
“I’m excited about this study because it teaches us something new about the human immune system,” said senior author Tariq Rana, PhD, professor of pediatrics at UC San Diego School of Medicine. “But these findings are also something researchers should keep in mind as they are designing new Zika virus vaccines and treatments that target the viral genome — some approaches won’t work unless they take methylation into account.”
 
In human cells, RNA is the genetic material that carries instructions from the DNA in a cell’s nucleus out to the cytoplasm, where molecular machinery uses those instructions to build proteins. Cells can chemically modify RNA to influence protein production. One of these modifications is the addition of methyl groups to adenosine, one of the building blocks that make up RNA. Known as N6-methyladenosine (m6A), this modification is common in humans and other organisms.
 
In contrast to humans, the entire genomes of some viruses, including Zika and HIV, are made up of RNA instead of DNA. These viruses hijack the host’s cellular machinery to translate its RNA to proteins. Rana and his team previously discovered that m6A plays an important role in HIV infection.
 
“After that, we decided to investigate m6A RNA in Zika virus as well, since we didn’t want to miss out on this important information the way we missed it for 30 years of HIV research,” Rana said.
 
When Zika virus infects a human cell, Rana’s team found, the cell modifies viral RNA with m6A as a means to get rid of the infection. RNA tagged with m6A is a beacon for human enzymes that come along and destabilize it. In addition, they found that this host response to Zika viral infection also induced specific m6A modifications on human RNA. These human RNA changes were not present in the absence of Zika virus.
 
To unravel the role of m6A in Zika virus infection of human cells growing in the laboratory, the researchers removed the human enzymes responsible for adding methyl groups to viral RNA. Without m6A, the viral RNA was more stable and viral replication increased, as compared to human cells with normal methylation enzymes. In contrast, silencing the human enzymes that remove methyl groups — increasing m6A methylation, in other words — decreased Zika virus production.
 
Next, Rana and team will investigate the role of RNA modifications in the viral life cycle, and how the human immune response is altered by various Zika virus strains. They are also developing small molecules to target specific RNA structures as a means to treat Zika virus infections.
 
Study co-authors include: Gianluigi Lichinchi, Yinga Wu, UC San Diego and Sanford Burnham Prebys Medical Discovery Institute; Boxuan Simen Zhao, Zhike Lu, Chuan He, University of Chicago and Howard Hughes Medical Institute; and Yue Qin, UC San Diego.
 
This research was funded, in part, by the National Institutes of Health (grants AI43198, AI125103, DA039562) and Howard Hughes Medical Institute.

Author: Heather Buschman, PhD

How One Patient's 'Crazy' Request for a New Womb Made History

Published in News
Saturday, 08 October 2016 22:13
TOCKHOLM — When the young Australian cervical cancer patient learned she had to lose her womb in order to survive, she proposed something audacious to the doctor who was treating her: She asked if she could have a womb transplant, so she could one day carry her own baby.
 
This was nearly two decades ago, when the Swedish doctor Mats Brannstrom was training to be a physician abroad.
 
“I thought she was a bit crazy,'' Brannstrom said.
 
But Brannstrom didn't dismiss her idea. Instead, after he returned to Sweden he began a series of painstaking research projects to learn whether it might be possible to transplant a womb, despite criticism that the unheard-of procedure was dangerous, medically unnecessary, and impossible.
 
Brannstrom went on to become the first doctor to deliver babies — five so far — from women with donated wombs. No other doctor in the world has succeeded, despite attempts in the U.S., Saudi Arabia and Turkey, and ongoing efforts in China, Britain, France, the Czech Republic and elsewhere.
 
The first of Brannstrom's patients' babies was born in 2014 and the fifth arrived in January; another is due in early 2017.
 
Brannstrom is working with doctors at Harvard Medical School and the Mayo Clinic to help women beyond Sweden get access to the procedure. Doctors at Baylor University in Texas, including two former members of Brannstrom's team, announced this week they performed four womb transplants. One was successful, but not yet ready to attempt a pregnancy.
 
Advertisement

Useful Sites

  • NCBI

    National Center for Biotechnology Information
  • LTO

    Lab Tests Online® by AACC
  • ASCP

    American Society for Clinical Pathology
  • ASM

    American Society for Microbiology
  • The Medical Library®

    Project of BioScience.pk
Advertisement

Connect With Us

Contact Us

All comments and suggestions about this web site are very welcome and a valuable source of information for us. Thanks!

Tel: +(92) 302 970 8985-6

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Website: https://www.bioscience.pk



This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.

Our Sponsors

InsightGadgets.comPathLabStudyTheMedicalLibrary.orgThe Physio ClubB2BPakistan.com

By using BioScience.pk you agree to our use of cookies to enhance your experience on this website.